Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
JA Fraietta, SF Lacey, EJ Orlando, I Pruteanu-Malinici… - Nature medicine, 2018 - nature.com
Tolerance to self-antigens prevents the elimination of cancer by the immune system 1 , 2 .
We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance …
We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance …
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
…, I Kulikovskaya, F Nazimuddin, VG Bhoj, EJ Orlando… - Nature medicine, 2018 - nature.com
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion
with CD19 – leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was …
with CD19 – leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was …
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
EJ Orlando, X Han, C Tribouley, PA Wood, RJ Leary… - Nature medicine, 2018 - nature.com
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19 –
relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast …
relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast …
Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction
…, R Pajarillo, S Agarwal, S Kuramitsu, EJ Orlando… - Cancer discovery, 2020 - AACR
Resistance to CART19 is a significant barrier to efficacy in the treatment of B-cell malignancies.
This work demonstrates that impaired death receptor signaling in tumor cells causes …
This work demonstrates that impaired death receptor signaling in tumor cells causes …
[HTML][HTML] A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical …
…, LM Treanor, EJ Orlando, J Mataraza, J Davis… - Cancer discovery, 2023 - AACR
Traditional CAR T-cell manufacturing requires extended ex vivo cell culture, reducing naive
and stem cell memory T-cell populations and diminishing antitumor activity. YTB323, which …
and stem cell memory T-cell populations and diminishing antitumor activity. YTB323, which …
Co-targeting of MDM2 and CDK4/6 with siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma: results from a …
…, A Jullion, EJ Orlando, G Clementi, J Sand Dejmek… - Clinical Cancer …, 2022 - AACR
Purpose: Well-differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcoma are
characterized by co-amplification of the murine double minute-2 (MDM2) and cyclin-dependent …
characterized by co-amplification of the murine double minute-2 (MDM2) and cyclin-dependent …
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome
Q Zhang, EJ Orlando, HY Wang… - Blood, The Journal …, 2020 - ashpublications.org
We describe here transdifferentiation of mantle cell lymphoma (MCL) into poorly differentiated
sarcoma (Sarc) after immunotherapy with autologous chimeric-antigen receptor T-cells …
sarcoma (Sarc) after immunotherapy with autologous chimeric-antigen receptor T-cells …
[HTML][HTML] Preservation of T-cell stemness with a novel expansionless CAR-T manufacturing process, which reduces manufacturing time to less than two days, drives …
…, M Greene, M Niederst, J Whalen, EJ Orlando… - Blood, 2021 - Elsevier
Background: Extended T-cell culture periods in vitro deplete the CAR-T final product of naive
and stem cell memory T-cell (T scm ) subpopulations that are associated with improved …
and stem cell memory T-cell (T scm ) subpopulations that are associated with improved …
YTB323 (rapcabtagene autoleucel) demonstrates durable efficacy and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma …
…, F Ciceri, D Pearson, EJ Orlando, L Yi, J Davis… - Blood, 2022 - ashpublications.org
Background: CD19-directed CAR-T cell therapies (tx) have shown efficacy in patients (pts)
with B-cell malignancies. However, many pts fail to respond or experience disease relapse …
with B-cell malignancies. However, many pts fail to respond or experience disease relapse …
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
JA Fraietta, SF Lacey, EJ Orlando… - Nature Medicine, 2021 - go.gale.com
… Lacey 1 2 3 , Elena J. Orlando 4 , Iulian Pruteanu-Malinici 4 , Mercy Gohil 2 , Stefan
Lundh 2 , Alina C. Boesteanu 2 , Yan Wang 2 , Roddy S. O'Connor 2 , Wei-Ting Hwang 5 …
Lundh 2 , Alina C. Boesteanu 2 , Yan Wang 2 , Roddy S. O'Connor 2 , Wei-Ting Hwang 5 …